Acumen Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Acumen Pharmaceuticals's earnings are forecast to decline at 7.7% per annum while its annual revenue is expected to grow at 82.1% per year. EPS is expected to decline by 4% per annum. Return on equity is forecast to be -99.1% in 3 years.
Wichtige Informationen
-7.7%
Wachstumsrate der Gewinne
-4.0%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.1% |
| Wachstumsrate der Einnahmen | 82.1% |
| Zukünftige Eigenkapitalrendite | -99.1% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 03 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -88 | -129 | -137 | 3 |
| 12/31/2025 | N/A | -100 | -104 | -115 | 4 |
| 12/31/2024 | N/A | -82 | -79 | -79 | 4 |
| 6/30/2024 | N/A | -65 | -56 | -56 | N/A |
| 3/31/2024 | N/A | -56 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -43 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2022 | N/A | -83 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -101 | -18 | -18 | N/A |
| 9/30/2021 | 0 | -93 | -17 | -17 | N/A |
| 6/30/2021 | 1 | -92 | -11 | -11 | N/A |
| 3/31/2021 | 1 | -32 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2019 | 2 | -8 | -7 | -7 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ABOS is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: ABOS is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: ABOS is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: ABOS is forecast to have no revenue next year.
Hohe Wachstumseinnahmen: ABOS is forecast to have no revenue next year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ABOS is forecast to be unprofitable in 3 years.